Cabozantinib in combination with atezolizumab as a first-line therapy in patients with radioiodinerefractory differentiated thyroid cancer: Results from cohort 18 of the phase 1b COSMIC-21 study.
Document Type
Presentation
Publication Date
10-19-2022
Keywords
oregon; chiles
Clinical Institute
Cancer
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
Taylor, M, "Cabozantinib in combination with atezolizumab as a first-line therapy in patients with radioiodinerefractory differentiated thyroid cancer: Results from cohort 18 of the phase 1b COSMIC-21 study." (2022). Articles, Abstracts, and Reports. 6876.
https://digitalcommons.providence.org/publications/6876
Comments
Presented at the American Thyroid Association Conference 2022 October 19-23; Montreal, Quebec Canada.